DigiPath Inc. (OTC: DIGP), a provider of reliable testing, education, training, and news coverage to the cannabis industry, recently announced a partnership with True North Laboratory of Ann Arbor, Michigan and Romer Labs, a leading global supplier of diagnostic solutions for food-borne pathogens, to investigate the applicability of its rapid diagnostic test kits for screening for pathogens and mycotoxins present in cannabis.
“This joint effort is expected to result in the first validated kit-based assays for food-borne pathogen and mycotoxin quality assurance testing on cannabis,” says Dr. Cindy Orser, DigiPath Labs’ Chief Science Officer. “As more states approve medical marijuana, the importance of validated studies such as this one planned for quality assurance will become of keen interest to officials from state public health departments who are responsible for ensuring the safety of medical marijuana.”
During a one-week study, Dr. Orser from Digipath Labs and two scientists from Romer Labs will execute validation studies at True North Laboratory in Ann Arbor, Michigan, where access to marijuana provides the plant matrix to conduct the testing to validate Romer Labs’ AgraQuant® Ochratoxin A ELISA System, which is quantitative from 2 to 40 ppb, and its AgraStrip® Aflatoxin Lateral Flow System, which features a 20 ppb aflatoxin cutoff sensitivity, and the fully quantitative AgraStrip® Aflatoxin WATEX test, which utilizes a water-based extraction process.
The cannabis testing market is expected to generate $850 million dollars in revenue by 2020, according to a new report by GreenWave Advisors. According to GreenWave Advisors Founder Matthew Karnes, cannabis testing is the most attractive subsector of the cannabis industry given its high barriers to entry, strong gross margins, and recurring revenue streams that are enhanced by potential expansion into services beyond testing.
Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.